Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
12/06/2025 23:05
June 12 (Reuters) - Blueprint Medicines Corp BPMC.O: BLUEPRINT MEDICINES ANNOUNCES DATA REINFORCING SUSTAINED CLINICAL EFFICACY AND WELL-TOLERATED SAFETY PROFILE OF LONG-TERM AYVAKIT®/AYVAKYT® (AVAPRITINIB) TREATMENT AT 2025 EHA AND EAACI CONGRESSES Source text: ID:nPn23Tv9Va Further company coverage: BPMC.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G